Investors
- Home
- Investors
Market Opportunity
The $16.2 billion market across hypertension devices ($12 billion) and corporate wellness ($4.2 billion) presents a significant opportunity. This is the first FDA-cleared solution for Day Apnea®-linked high blood pressure, addressing the needs of 116 million US adults with hypertension. The device also targets Screen Apnea®, affecting 80% of desk workers (Microsoft, 2023), and aims to reduce corporate healthcare costs. With zero direct competitors in real-time nasal/oral breathing monitoring and 7 patents pending for its airflow sensors, CMAP possesses unmatched growth potential through sleep clinic partnerships and recurring revenue from sensor replacements. So
- $16.2B Market Opportunity
- FDA-Cleared Apnea Solution
- Patented Breathing Monitoring
Revenue Streams
| Category | Year 1 | Year 3 |
|---|---|---|
| Device Sales ($299-$499/unit) |
$8M | $45M |
| Consumables (Cannulas/sensors) |
$1.5M | $15M |
| Licensing (App/clinical partnerships) |
$0.5M | $8M |
| Total | $10M | $68M |
Clinical Proof
CMAP delivers clinically validated results, including a 70% reduction in Screen Apnea® episodes and 30% faster blood pressure reduction compared to RESPeRATE in controlled trials. The device’s efficacy is backed by seven pending patents for its proprietary airflow sensor technology, with ongoing FDA-cleared studies for hypertension therapy. These outcomes position CMAP as the only medical-grade solution addressing both daytime breathing disorders and cardiovascular health through non-invasive monitoring.
Request for a Call Back
Let's Connect Instantly
Have a question or need assistance? We’re here to help—get in touch now!
Location
- © 2025 Breethwell. All rights reserved